REACTIONS and they may be accompanied by other adrenergic effects. Treat the alert patient who has taken excessive oral medication by emptying the stomach by means of induced emesis, followed by gastric lavage. In the unconscious patient, secure the airway with a cuffed endotracheal tube before beginning lavage (do not induce emesis). Instillation of activated charcoal slurry may help reduce absorption of terbutaline sulfate. Maintain adequate respiratory exchange. Provide cardiac and respiratory support as needed. Continue observation until symptom-free.

DOSAGE AND ADMINISTRATION:
Tablet: The usual oral dose of Brethin for adults is 5 mg administered 3 times in 24 hours. If side effects are particularly disturbing, the dose may be reduced to 2.5 mg three times daily, and still provide a clinically significant improvement in pulmonary function. A dose of 2.5 mg, three times daily, also is recommended for children in the 12 to 15 years group.

Syrup: For adults 2–3 teaspoonfuls (10–15 ml) 3 times in 24 hours. For children 0.075 mg (0.25 ml) / kg body weight 3 times in 24 hours. Under 3 years of age ½ teaspoonful, between 3–5 years ½ to 1 teaspoonful, between 6–12 years 1–1 ½ teaspoonful, for over 12 years of age is adult dose.

HOW SUPPLIED:
Brethin Tablets 2.5 mg are supplied in blister pack of 10x10's.

Brethin Syrup 1.5 mg / 5 ml is supplied in bottle of 60 ml.

STORAGE:
Store below 30°C, in a dry place, protect from light.
To be dispensed on the prescription of a registered medical practitioner only.
Keep out of the reach of children.

خوراک: ڈاکٹر کی ہدایت کے مطابق استعمال کریں۔
دوا کو ۳۰ ڈگری سینٹی گریڈ سے کم درجہ حرارت پر خشک جگہ پر رکھیں،
روشنی سے بچائیں۔ صرف رجسٹرڈ ڈاکٹر کے نسخے پر فروخت کریں۔
بچوں کی پہنچ سے دُور رکھیں۔

Manufactured by:
Platinum Pharmaceuticals (Pvt.) Ltd.
A-20, North Western Industrial Zone,
Bin Qasim, Karachi-75020, Pakistan.

QAR No. AW17-0194

Brethin®

(Terbutaline sulfate)
Tablets & Syrup

بریتھن
(ٹربیوٹالین سلفیٹ)
گولیاں اور سیرپ

COMPOSITION
Each tablet contains:
Terbutaline sulfate .....… 2.5 mg
Product Complies U.S.P. Specs.

Each 5 ml syrup contains:
Terbutaline sulfate ..... 1.5 mg
Product Complies Innovator's Specs.

INDICATIONS AND USAGE:
Bronchial asthma, chronic bronchitis, emphysema and other lungs diseases where bronchospasm is a complicating factor. Also indicated for the management of uncomplicated premature labour.

CONTRAINDICATIONS:
Hypersensitivity to terbutaline or any of its ingredients. Any condition of the mother or fetus in which prolongation of pregnancy is hazardous e.g. antepartum haemorrhage, severe toxaemia, intrauterine infections, threatened abortion during first or second trimesters or compression of the cord.

WARNINGS:
Beta 2 agonists have an arrhythmogenic potential. Hypokalaemia may result when given along with xanthine derivatives, steroids and diuretics or by hypoxia. It is recommended serum potassium levels to be monitored in such situations. Brethin does not affect the ability to drive or operate machinery.

Pregnancy & Lactation: No teratogenic effects have been observed in animals or patients. However, caution should be exercised during the first trimester of pregnancy. Terbutaline is excreted in breast milk. An influence on the suckling child is however unlikely at therapeutic doses.

PRECAUTIONS:
Brethin should be used with caution in patients with diabetes, hypertension, hyperthyroidism, and a history of seizures. As with other sympathomimetic bronchodilator agents, Brethin should be administered cautiously to cardiac patients, especially those with associated arrhythmias.

ADVERSE REACTIONS:
Commonly observed side effects include nervousness and tremor. Other reported reactions include headache, increased heart rate, palpitations, drowsiness, nausea, vomiting, sweating, and muscle cramps. These reactions are generally transient in nature and usually do not require treatment. The frequency of these side effects appears to diminish with continued therapy. In general, all the side effects observed are characteristic of those commonly seen with sympathomimetic amines.

OVERDOSAGE:
Overdosage experience is limited. Excessive beta-adrenergic receptor stimulation may augment the signs or symptoms listed under ADVERSE